The enrichment of the FoxO pathway in up-regulated DEGs is also consistent with the role of ESRRB as a tumor suppressor in breast and prostate cancers, as well as the association of ESRRB overexpression with improved prognosis [79,80,81,82]. Here, ESRRB is linked to prostate carcinoma.